Suspected Rivaroxaban-Induced Anaphylaxis Secondary to Ingestion of Rivaroxaban and Nimesulide Without Cross-Reactivity to Dabigatran – A Case Report

References

• Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300–1305.e2. doi:10.1016/j.amjmed.2015.05.044
   PubMed Web of Science ®Google Scholar
• Badreldin H, Nichols H, Rimsans J, Carter D. Evaluation of anticoagulation selection for acute venous thromboembolism. J Thromb Thrombolysis. 2017;43(1):74–78. doi:10.1007/s11239-016-1417-5
   PubMed Web of Science ®Google Scholar
• Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol. 2017;73(11):1417–1425. doi:10.1007/s00228-017-2296-1
   PubMed Web of Science ®Google Scholar
• Bezabhe WM, Bereznicki LR, Radford J, et al. Ten-year trends in the use of oral anticoagulants in Australian general practice patients with atrial fibrillation. Front Pharmacol. 2021;12:586370. doi:10.3389/fphar.2021.586370
   PubMed Web of Science ®Google Scholar
• Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10(1):61–75. doi:10.1038/nrd3185
   PubMed Web of Science ®Google Scholar
• Tomás-Pérez M, De Las Vecillas L. Allergy to rivaroxaban cross-reactivity with other direct anticoagulants and the role of the basophil activations test: a case report. J Investig Allergol Clin Immunol. 2023;33(5). doi:10.18176/jiaci.0883
   PubMed Web of Science ®Google Scholar
• Wu Z, Ma Y. Hypersensitivity reaction from Rivaroxaban. Am J Med Sci. 2021;361(5):679–680. doi:10.1016/j.amjms.2020.11.002
   PubMed Web of Science ®Google Scholar
• Khan FY, Sulaiman TO. Anaphylaxis following rivaroxaban ingestion: report of an extremely rare case. Pan Afr Med J. 2021;38. doi:10.11604/pamj.2021.38.333.28401
   Web of Science ®Google Scholar
• Patil T, Ikekwere C. A case report of rivaroxaban-induced urticaria and angioedema with possible cross-reaction to dabigatran. J Med Cases. 2019;10(12):359–363. doi:10.14740/jmc3399
   PubMedGoogle Scholar
• Rudd KM, Panneerselvam N, Patel A. Rash associated with rivaroxaban use. Am J Health Sys Pharm. 2018;75(6):347–349. doi:10.2146/ajhp160985
   PubMed Web of Science ®Google Scholar
• Sasson E, James M, Russell M, Todorov D, Cohen H. Probable rivaroxaban-induced full body rash: a case report. J Pharm Pract. 2018;31(5):503–506. doi:10.1177/0897190017722872
   PubMed Web of Science ®Google Scholar
• Banaga Y, Mohmmed K, Mustafa H, Barrett J. Angioedema 2 months after administration of rivaroxaban (Xarelto). J Clin Case Rep. 2017;7(12). doi:10.4172/2165-7920.10001059
   PubMedGoogle Scholar
• Chiasson CO, Canneva A, Roy FO, Doré M. Rivaroxaban-induced hypersensitivity syndrome. CJHP. 2017;70(4). doi:10.4212/cjhp.v70i4.1681
   Google Scholar
• Vernon HM, Nielsen AK, O’Bryan EC. Hypersensitivity reaction after administration of rivaroxaban (Xarelto). Am J Emerg Med. 2016;34(7):1325.e1–1325.e2. doi:10.1016/j.ajem.2015.12.021
   PubMed Web of Science ®Google Scholar
• Radu C, Barnig C, de Blay F. Rivaroxaban-induced drug reaction with eosinophilia and systemic symptoms. J Investig Allergol Clin Immunol. 2016;26(2):124–126. doi:10.18176/jiaci.0027
   PubMed Web of Science ®Google Scholar
• Snyder DJ, Matusik FB. Rivaroxaban-induced serum sickness after total knee arthroplasty. Am J Health Sys Pharm. 2015;72(18):1567–1571. doi:10.2146/ajhp140549
   PubMed Web of Science ®Google Scholar
• Barrett P, Vuppalanchi R, Masuoka H, Chalasani N. Severe drug-induced skin and liver injury from rivaroxaban. Dig Dis Sci. 2015;60(6):1856–1858. doi:10.1007/s10620-014-3504-9
   PubMed Web of Science ®Google Scholar
• Altin C, Ozturkeri OAY, Gezmis E, Askin U. Angioedema due to the new oral anticoagulant rivaroxaban. Ann Card Anaesth. 2014;2(17):173–174. doi:10.4103/0971-9784.129888
   Google Scholar
• Yates J, Choudhry M, Keys G. A case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patient: suspected rivaroxaban hypersensitivity in a surgical patient. J Clin Pharm Ther. 2013;38(2):159–161. doi:10.1111/jcpt.12013
   PubMed Web of Science ®Google Scholar
• Hofmeier KS, Bircher AJ. Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs. Allergo J Int. 2015;24(2):58–66. doi:10.1007/s40629-015-0048-2
   PubMedGoogle Scholar
• Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96(13):7563–7568. doi:10.1073/pnas.96.13.7563
   PubMed Web of Science ®Google Scholar
• Caiazzo E, Ialenti A, Cicala C. The relatively selective cyclooxygenase-2 inhibitor nimesulide: what’s going on? Eur J Pharmacol. 2019;848:105–111. doi:10.1016/j.ejphar.2019.01.044
   PubMed Web of Science ®Google Scholar
• Aun MV, Blanca M, Garro LS, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. J Allergy Clin Immunol. 2014;2(4):414–420. doi:10.1016/j.jaip.2014.03.014
   Web of Science ®Google Scholar
• Dubini M, Marraccini P, Gagliardi C, Marelli S, Rivolta F. Anaphylaxis to nimesulide. Ann Allergy Asthma Immunol. 2021;127(1):144–145. doi:10.1016/j.anai.2021.04.007
   PubMed Web of Science ®Google Scholar
• Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391–397. doi:10.1016/j.jaci.2005.12.1303
   PubMedGoogle Scholar
• Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi:10.1016/j.waojou.2020.100472
   PubMed Web of Science ®Google Scholar
• Lott C, Truhlář A, Alfonzo A, et al. European Resuscitation Council Guidelines 2021: cardiac arrest in special circumstances. Resuscitation. 2021;161:152–219. doi:10.1016/j.resuscitation.2021.02.011
   PubMed Web of Science ®Google Scholar
• Černiauskienė M, Bagdonaitė L, Karčiauskaitė D, Kvedarienė V. Prevalence and variability of allergen-specific immunoglobulin E in patients with elevated tryptase levels. Med Sci Monit. 2022;28. doi:10.12659/MSM.937990
   Web of Science ®Google Scholar
• Muraro A, Worm M, Alviani C, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy. 2022;77(2):357–377. doi:10.1111/all.15032
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Hakkenbrak NAG, Truijers M. Life-threatening non-allergic drug hypersensitivity reaction as a very rare side effect of rivaroxaban administration in the Netherlands. Vasc Endovascular Surg. 2021;55(7):749–751. doi:10.1177/15385744211004763
   PubMed Web of Science ®Google Scholar
• Montañez MI, Mayorga C, Bogas G, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front Immunol. 2017;8:614. doi:10.3389/fimmu.2017.00614
   PubMed Web of Science ®Google Scholar
• World Health Organisation. VigiAccess database. Available from: https://www.vigiaccess.org/. Accessed December 28, 2022.
   Google Scholar